Fusion proteins specific for CD137 and GPC3
US-12486330-B2 · Dec 2, 2025 · US
This page is not indexed by search engines while we improve data quality.
Olwill Shane patents
Olwill Shane is listed as an inventor on 37 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Olwill Shane |
| Total patents | 37 |
| First publication | Dec 15, 2016 |
| Latest publication | Dec 2, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Proteins specific for CD137
US-12195503-B2 · Jan 14, 2025 · US
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
US-2024166763-A1 · May 23, 2024 · US
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
US-2024166764-A1 · May 23, 2024 · US
Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
US-11919931-B2 · Mar 5, 2024 · US
Lipocalin muteins with binding affinity for LAG-3
US-11773147-B2 · Oct 3, 2023 · US
Multimeric immunomodulator targeting 4-1bb
US-2023227568-A1 · Jul 20, 2023 · US
Novel Fusion Proteins Specific for CD137 and GPC3
US-2022153864-A1 · May 19, 2022 · US
Novel proteins specific for cd137
US-2022144901-A1 · May 12, 2022 · US
Lipocalin muteins with binding affinity for lag-3
US-2022098253-A1 · Mar 31, 2022 · US
Recent patents
Latest publications not already listed above.
Proteins specific for CD137
US-11261221-B2 · Mar 1, 2022 · US
Anti-cancer fusion polypeptide
US-2021403516-A1 · Dec 30, 2021 · US
Novel fusion protein specific for cd137 and pd-l1
US-2021363257-A1 · Nov 25, 2021 · US
Lipocalin muteins with binding affinity for LAG-3
US-11168119-B2 · Nov 9, 2021 · US
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
US-2021246219-A1 · Aug 12, 2021 · US
Anti-cancer fusion polypeptide
US-2021198380-A1 · Jul 1, 2021 · US
Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)
US-11034738-B2 · Jun 15, 2021 · US
Multi-specific polypeptide useful for localized tumor immunomodulation
US-10927154-B2 · Feb 23, 2021 · US
Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response
US-10927156-B2 · Feb 23, 2021 · US
Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides
US-10913778-B2 · Feb 9, 2021 · US
Anti-cancer fusion polypeptide
US-10865250-B2 · Dec 15, 2020 · US
Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereof
US-2020148733-A1 · May 14, 2020 · US
Novel proteins specific for angiogenesis
US-2020140501-A1 · May 7, 2020 · US
Novel proteins specific for lag-3
US-2020048317-A1 · Feb 13, 2020 · US
Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof
US-10526382-B2 · Jan 7, 2020 · US
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
US-10526384-B2 · Jan 7, 2020 · US
Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
US-10501510-B2 · Dec 10, 2019 · US
Lipocalin muteins with binding affinity for lag-3
US-2019345207-A1 · Nov 14, 2019 · US
Novel proteins specific for lag-3
US-2019031729-A1 · Jan 31, 2019 · US
Anti-cancer fusion polypeptide
US-2019010248-A1 · Jan 10, 2019 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Pieris Pharmaceuticals Gmbh | 37 |
| Pieris Ag | 1 |
| Servier Lab | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K14/47 | 35 |
| A61P35/00 | 32 |
| A61K38/00 | 24 |
| C07K2319/30 | 18 |
| C07K2319/00 | 16 |